Eptifibatide is a platelet aggregation inhibitor indicated for treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI), among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Eptifibatide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI). Treatment of patients undergoing PCI (including intracoronary stenting).
Source: US FDA prescribing information
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa. When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the eptifibatide infusion, this is thought to result from dissociation of eptifibatide from the platelet.
Source: US FDA prescribing information
Before infusion of eptifibatide injection, the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured. The activated partial thromboplastin time (aPTT) should be maintained between 50 and 70 seconds unless PCI is to be performed. In patients treated with heparin, bleeding can be minimized by close monitoring of the aPTT and ACT. ACS or PCI: 180 mcg/kg IV bolus as soon as possible after diagnosis followed by infusion at 2 mcg/kg/min. PCI: Add a second 180 mcg/kg bolus at 10 minutes. In patients with creatinine clearance less than 50 mL/min, reduce the infusion to 1 mcg/kg/min.
Source: US FDA prescribing information
Treatment with eptifibatide is contraindicated in patients with: A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another parenteral GP IIb/IIIa inhibitor Dependency on renal dialysis Hypersensitivity to eptifibatide or any component of the product (hypersensitivity reactions that occurred included anaphylaxis and urticaria) Bleeding diathesis or bleeding within the previous 30 days.
Source: US FDA prescribing information
Eptifibatide can cause serious bleeding. If bleeding cannot be controlled, discontinue eptifibatide immediately. Minimize vascular and other traumas. If heparin is given concomitantly, monitor aPTT or ACT. Thrombocytopenia: Discontinue eptifibatide and heparin. Monitor and treat condition appropriately.
Source: US FDA prescribing information
The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding Bleeding and hypotension are the most commonly reported adverse reactions.
Source: US FDA prescribing information
Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors.
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted between 15° and 30°C (59° and 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Eptifibatide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Eptifibatide 75 mg/100 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Eptifibatide 20 mg/10 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Eptifibatide 200 mg/100 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Eptifibatide in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Eptifibatide and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Eptifibatide on 18 May 1998, according to Drugs@FDA.
Yes. Eptifibatide has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Eptifibatide must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Eptifibatide is classified under ATC code B01AC16 (Eptifibatide).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.